Figure 13 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446

Figure 13 The volume change (mm3) for treatment groups in vivo for EMT-6/P and EMT-6/V. Only statistically significant associations are shown. Positive control (PBS and tween 20%), baicalin 75 mg/kg/day, EGCG: 50 mg/kg/day, baicalin and EGCG combination 75 and 50 mg/kg/day respectively, vincristine 2mg/kg/every other day, and same doses were used in the triple therapy.